A randomised crossover trial of chemotherapy in the home: patient preferences and cost anaiysis
2000; Wiley; Volume: 173; Issue: 3 Linguagem: Inglês
10.5694/j.1326-5377.2000.tb125563.x
ISSN1326-5377
AutoresDanny Rischin, Michelle A White, Jane Matthews, Guy C. Toner, Kathryn Watty, Anthony J Sulkowski, Jan L Clarke, Lois Buchanan,
Tópico(s)Cancer survivorship and care
ResumoMedical Journal of AustraliaVolume 173, Issue 3 p. 125-127 Research A randomised crossover trial of chemotherapy in the home: patient preferences and cost anaiysis Danny Rischin MB BS(Hons), FRACP, Corresponding Author Danny Rischin MB BS(Hons), FRACP Consultant Medical Oncologist, Division of Haematology and Medical Oncology drischin@petermac.unimelb.edu.au Peter MacCallum Cancer Institute, Melbourne, VICReprints will not be available from the authors. Correspondence: Dr D Rischin, Division of Hematology and Medical Oncology, Peter Maccallum Cancer Institute, Locked Bag 1, A'Beckett Street, Melbourne, VIC 8006. drischin@petermac.unimelb.edu.auSearch for more papers by this authorMichelle A White MBBS(Hons), FRACP, Michelle A White MBBS(Hons), FRACP Clinical Fellow, Division of Haematology and Medical Oncology Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorJane P Matthews BSc(Hons), PhD, AStat, Jane P Matthews BSc(Hons), PhD, AStat Director, Statistical Centre Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorGuy C Toner MD, BS, FRACP, Guy C Toner MD, BS, FRACP Head of Medical Oncology, Division of Haematology and Medical Oncology Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorKathryn Watty RN, RM, Kathryn Watty RN, RM Clinical Nurse Consultant, Division of Nursing Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorAnthony J Sulkowski RN, BEd, Anthony J Sulkowski RN, BEd Clinical Nurse Consultant, Division of Nursing Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorJan L Clarke RN, Jan L Clarke RN Clinical Nurse Consultant, Division of Nursing;Search for more papers by this authorLois Buchanan RN, RM, Lois Buchanan RN, RM Clinical Nurse Consultant,- Division of Nursing Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this author Danny Rischin MB BS(Hons), FRACP, Corresponding Author Danny Rischin MB BS(Hons), FRACP Consultant Medical Oncologist, Division of Haematology and Medical Oncology drischin@petermac.unimelb.edu.au Peter MacCallum Cancer Institute, Melbourne, VICReprints will not be available from the authors. Correspondence: Dr D Rischin, Division of Hematology and Medical Oncology, Peter Maccallum Cancer Institute, Locked Bag 1, A'Beckett Street, Melbourne, VIC 8006. drischin@petermac.unimelb.edu.auSearch for more papers by this authorMichelle A White MBBS(Hons), FRACP, Michelle A White MBBS(Hons), FRACP Clinical Fellow, Division of Haematology and Medical Oncology Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorJane P Matthews BSc(Hons), PhD, AStat, Jane P Matthews BSc(Hons), PhD, AStat Director, Statistical Centre Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorGuy C Toner MD, BS, FRACP, Guy C Toner MD, BS, FRACP Head of Medical Oncology, Division of Haematology and Medical Oncology Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorKathryn Watty RN, RM, Kathryn Watty RN, RM Clinical Nurse Consultant, Division of Nursing Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorAnthony J Sulkowski RN, BEd, Anthony J Sulkowski RN, BEd Clinical Nurse Consultant, Division of Nursing Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this authorJan L Clarke RN, Jan L Clarke RN Clinical Nurse Consultant, Division of Nursing;Search for more papers by this authorLois Buchanan RN, RM, Lois Buchanan RN, RM Clinical Nurse Consultant,- Division of Nursing Peter MacCallum Cancer Institute, Melbourne, VICSearch for more papers by this author First published: 01 August 2000 https://doi.org/10.5694/j.1326-5377.2000.tb125563.xCitations: 43AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Objectives To determine patient preferences and cost differences between home-based and hospital-based chemotherapy. Design Randomised crossover trial. Setting A tertiary cancer hospital in Melbourne, Victoria. Participants 20 patients who required chemotherapy suitable for administration at home. Interventions Patients were assigned at random to receive their first chemotherapy treatment in either the home or the hospital and the second treatment in the alternative setting. Main outcome measures Patient preference, costs. Results There was universal agreement by the 20 patients in the randomised trial that home-based chemotherapy was the preferred option (P< 0.0001). No problems were nominated by the patients as being associated with home-based chemotherapy. Home-based treatment was estimated to result in an increased cost of $83 (P=0.0002) for each chemotherapy treatment compared with hospital-based treatment. Reported advantages for chemotherapy in the home included the elimination of travel, reduction in treatment-associated anxiety, reduction in the burden on carers and family, and the ability to continue other duties. There were no significant complications associated with administration of chemotherapy in the home. Conclusions Patients prefer home-based chemotherapy to hospital-based treatment. The future of chemotherapy-in-the-home programs in Australia will depend on whether patient preferences are deemed to offset any potential increase in costs. Citing Literature Volume173, Issue3August 2000Pages 125-127 RelatedInformation
Referência(s)